

Business Economy

Posted at: Dec 28 2021 6:00PM



Dr Reddy labs get DCGI approval to manufacture & market anti-viral drug 'Molnupiravir'

Hyderabad, Dec 28 (UNI) Dr. Reddy's Laboratories Limited on Tuesday announced that it has received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug Molnupiravir capsules 200mg in India for the treatment of adult patients with COVID-19 with SpO2 >93% and who have high risk of progression of the disease including hospitalisation or death.

Dr. Reddy's will soon launch its Molnupiravir capsules 200mg under the brand name 'Molflu™' across India, Hyderabad-based Pharma giant said in a release here.

Earlier this year, the company entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 Low and Middle Income Countries (LMICs).

In a first-of-its-kind collaboration in the Indian pharmaceutical industry, Dr. Reddy's-led consortium of pharma companies collaborated to jointly sponsor, supervise and monitor the Phase III clinical trial in India, and presented its findings to the Subject Expert Committee (SEC).

As a vertically integrated company, Dr. Reddy's is able to manufacture the Active Pharmaceutical Ingredient (API) as well as the formulation for Molnupiravir, and has made adequate capacity preparations to ensure that it is able to help patients in India as well as in patient populations in need around the world.

Commenting on the development, Dr Reddy's Co-Chairman and Managing Director G.V. Prasad, said, the approval to launch Molnupiravir is an important development not only as a treatment option, but also for the collaborative manner in which Indian pharma companies came together. Throughout the pandemic, we have sought to create diverse collaborations and partnerships to meet unmet medical needs of as many patients as possible globally.

Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. It has been studied by Merck & Company., Inc., in collaboration with Ridgeback Biotherapeutics in a Phase III trial for the treatment of non-hospitalized patients with confirmed COVID-19 globally.

It has received approvals from regulatory authorities in the U.K., U.S and Japan.

UNI KNR CS1755

Tags: #Dr Reddy labs get DCGI approval to manufacture & market anti-viral drug 'Molnupiravir'

UNI Photo



GUWAHATI, DEC 29 (UNI):- Members of All Assam Students' Union (AASU) staging protest against assault and lathi charge on their members in Dibrugarh and lathi charge by

Other Links

UNIVARTA (News Agency)
Indian News Agency

UNI-Urdu Service(News Agency)
Indian News Agency

Newsrap

Newsrap1

More News



NRIs and OCIs don't need prior RBI nod for buying immovable properties in India

29 Dec 2021 | 5:11 PM

New Delhi, Dec 29 (UNI) Reserve Bank of India (RBI) on Wednesday clarified that NRIs (Non-resident Indians) and OCIs (Overseas Citizen of India) do not require prior approval of the central bank for acquisition and transfer of immovable property in India other than agricultural land, farm house and plantation property.

[see more..](#)



Sensex down 90 99 points

29 Dec 2021 | 5:09 PM

Mumbai, Dec 29 (UNI) The BSE Sensex on Wednesday slipped by 90.99 points to settle at 57,806.49 as selling was seen in metal, materials, power and utilities stocks.

[see more..](#)

Amara Raja to invest in InoBat Auto for E-mobility

29 Dec 2021 | 4:58 PM

Tirupati, Dec 29 (UNI) Amara Raja Batteries Limited (ARBL), India's leading industrial and automotive battery major, on Wednesday announced plans to invest in InoBat Auto, a European technology developer and manufacturer of premium innovative batteries, for E-mobility.

[see more..](#)

SBI down 1 45 pc to Rs 454 25

29 Dec 2021 | 4:56 PM

Mumbai, Dec 29 (UNI) SBI on Wednesday fell by 1.45 pc to Rs 454.25 a major loser in 30 scrips of BSE.

[see more..](#)

Rupee falls 8 paise against USD

29 Dec 2021 | 4:50 PM

Mumbai, Dec 29 (UNI) The Rupee on Wednesday slipped by 8 paise to close at 74.73 against the Dollar on rising demand for the US currency by bankers and exporters, dealers at the Foreign Exchange said.

[see more..](#)



Wednesday, Dec 29 2021 | Time 17:25 Hrs(IST)

[Home](#) [News](#) [Photo](#) [Hindi](#) [Urdu](#) [PRESS RELEASES](#) [Web Hits](#) [FeedBack](#)

[About UNI](#) [Contact us](#) [SiteMap](#) [JOBS](#) [Tender](#) [Terms of Use](#) [Disclaimer](#)

Privacy policy

Follow us on :-



Copyright @ United News of India. All rights reserved.

Contact us at :-

United News of India

9, Rafi Marg, New Delhi-110001

Email: vsat@uniindia.com

Contact: 011-23714434 / 23357614 (O)